PPT-Treatments in Ischemic Stroke:

Current and Future Published in journal of European neurology On august 2022 INTRODUCTION Despite progress in the understanding of the pathophysiological mechanisms underlying stroke over the past 3 decades concerning early diagnosis and the development of protocols that have reduced the doortoneedle time for acute ischemic stroke AIS treatment several clinical gaps remain unsolved. : . A New Path for Treatment of Endothelial Dysfunction and CVD. A Webinar Presentation on December 8. th. , 2016 2PM PST. Robert A. Kloner MD, PhD. Director of the Cardiovascular Research Institute of HMRI. Seattle, WA. Irving . Kron, M.D.. Professor and Chairman Department of Surgery. University of Virginia Hospital . Charlottesville, Virginia. AATS Ischemic MR Guideline Writing Group Roster. Irving L. Kron, Chair. Children. A Brief . Overview . Tammy . Hennika. , M.D.. Childhood stroke activations. What neuroimaging?. What labs?. What is the treatment? . Can we give . tPA. ?. If not a stroke, what could it be? . Seattle, WA. Irving . Kron, M.D.. Professor and Chairman Department of Surgery. University of Virginia Hospital . Charlottesville, Virginia. AATS Ischemic MR Guideline Writing Group Roster. Irving L. Kron, Chair. Medical Director. IU Health Methodist Hospital. Comprehensive Stroke Center. Disclosures. None. Stroke Statistics. Heart Disease and Stroke Statistics 2014. ~795,000 new or recurrent strokes/year. 87% Ischemic, 10% ICH, 3% SAH. Objectives. Review brain anatomy and physiology, including vascular supply. Review the differences between ischemic/thrombotic and hemorrhagic disruptions in cranial blood flow. Review signs and symptoms of stroke and highlight differences in special populations. (stroke). Made by : . Dani. . mamo. . Cerebrovascular diseases. *. Cerebrovascular diseases include some of the most common and devastating disorders:. 1-ischemic stroke. 2-hemorrhagic stroke. *. and cerebrovascular anomalies such as :. 06/07/2015. ISCHEMIC HEART DISEASE. INTRODUCTION. PATHOPHYSIOLOGY. IMAGING IN ISCHAEMIC . HEART . DISEASE (IHD). COMPLICATION OF IHD. ISCHEMIC HEART DISEASE. INTRODUCTION. Ischaemic heart disease (IHD), the leading cause of . BDS 2017 BATCH. DR. WALEEM AHMAD. HEMIPLEGIA. Hemiparesis. , or unilateral paresis, is weakness of one entire side of the body (. hemi-.  means "half"). . Hemiplegia.  is, in its most severe form, complete paralysis of half of the body. Hemiparesis and hemiplegia can be caused by different medical conditions, including congenital causes, trauma, tumors, or stroke. OBJECTIVE. นักศึกษาแพทย์ทราบแนวทางการประเมินและวินิจฉัยผู้ป่วยโรคหลอดเลือดสมองเบื้องต้นได้. Assist.Lect. . . Shaymaa. . Hasan. Abbas. DESIRED TREATMENT OUTCOMES. The short-term goals of treatment for acute ischemic stroke include reducing secondary brain damage by re-establishing and maintaining adequate perfusion to marginally ischemic areas of the brain and to protect these areas from the effects of ischemia (i.e., . Content. : Archana Hinduja, MD; M . Sohel. Ahmed, MD. Slides. : Archana Hinduja, MD; M . Sohel. Ahmed, MD. Editors’ Note: Global Considerations. The intent of the editors, authors, and reviewers of this ENLS topic was not to address all the variations in international practice for the different diseases. We have discussed major practice variances (e.g., the availability of diagnostic testing, or the type of medications used) and encourage learners to use the ENLS algorithms as a framework on which any relevant local practice guidelines can be incorporated.. S. urvivors for Stroke . P. revent. I. on. and . RE. covery. Mean reduction of 9/4 mm Hg. Of course you want to join the first ICH prevention study – . ASPIRE. – in recent NIH history! . This is a great trial to contribute to an active clinical practice question and a wonderful way to build out your StrokeNet trial portfolio!. (n . = 6,589). SOCRATES. Primary outcome, death, MI or stroke, for ticagrelor vs. aspirin: . 6.7% . vs. 7.5%, HR = 0.89, 95% CI . 0.78-1.01. , . p = 0.07. Death: 1.0% vs. 0.9%, . p = 0.36; All . strokes: 5.9% vs. 6.8%, .